Table 4.
Analyses of risk factors for poor clinical outcomes in the TB-HBV group (n = 58)
| Factors | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P-value | OR | 95%CI | P-value | |
| Age > 50 | 3.791 | 1.23, 11.69 | 0.020 | 3.317 | 0.91, 12.04 | 0.068 |
| Male | 2.625 | 0.27, 25.14 | 0.402 | – | – | – |
| Alcohol intake > 40 g/d | 5.069 | 0.58, 44.36 | 0.143 | 2.744 | 0.19, 40.15 | 0.461 |
| INH + RFP | 1.173 | 0.36, 3.80 | 0.790 | – | – | – |
| Latency < 1 month | 0.979 | 0.21, 4.57 | 0.978 | – | – | – |
| Hepatocellular DILI | 1.507 | 0.47, 4.80 | 0.488 | – | – | – |
| Cirrhosis | 4.76 | 1.44, 15.76 | 0.011 | 6.320 | 1.53, 26.06 | 0.011 |
| HBV DNA > 20,000 IU/ml | 3.800 | 1.16, 12.52 | 0.028 | 5.808 | 1.37, 24.64 | 0.017 |
| NA treatment | 1.071 | 0.36, 3.33 | 0.905 | – | – | – |
Only variables with P < 0.200 in the univariate analysis were included in the multivariate analysis
Abbreviations: INH isoniazid, RFP rifampin, DILI drug-induced liver injury, HBV hepatitis B virus, NA nucleos(t)ide analogue